AEGiS-WSJ: Panacos Gains $18.3 Million Wall Street JournalImportant note: Information in this article was accurate in 2004. The state of the art may have changed since the publication date.
Click here to return to Wall Street Journal main menu




DonateNow



Panacos Gains $18.3 Million

Wall Street Journal - May 18, 2004

Panacos Pharmaceuticals Inc., Gaithersburg, Md., gained $18.3 million in series C funding. The round was led by Ampersand Ventures and A.M. Pappas & Associates and included Mitsui & Co. Venture Partners Inc., Novo A/S, New England Partners Capital LP, William Harris Investors, Lakeview Capital Management and the Maryland Dept. of Business and Economic Development. Panacos (www.panacos.com) is a drug-discovery company focused on the treatment of HIV and other viral diseases.


040518
WJ040509

Copyright © 2004 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2004. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2004. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .